Status:
RECRUITING
Incidence and Clinical Impact of Serum Hyperamylasemia (POH) After Pancreatectomy on Postoperative Outcome and Patient Safety
Lead Sponsor:
Technische Universität Dresden
Conditions:
Pancreatectomy
Hyperamylasemia
Eligibility:
All Genders
18-85 years
Brief Summary
Recent evidence suggests that postoperative hyperamylasemia (POH) is a predictor of morbidity after pancreatectomy. This is based on the assumption that pancreatitis after pancreatectomy (PPAP) is a m...
Eligibility Criteria
Inclusion
- All patients undergoing pancreatic resection for malignant and benign disease with or without pancreatic anastomosis
- Patients aged 18-85 years
- Willingness to participate as demonstrated by giving a written informed consent.
Exclusion
- Necrosectomy (endoscopic or open) for primary acute pancreatitis or within laparotomy
- Age less than 18 years
- Surgical drainage procedures without pancreatic resection (cystojejunostomy for pancreatic pseudocysts)
- One-stage total pancreatectomy
- Missing written consent
Key Trial Info
Start Date :
July 18 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06126601
Start Date
July 18 2023
End Date
April 1 2026
Last Update
February 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Dresden, Dept. Visceral, Thoracic and Vascular Surgery
Dresden, Germany, 01307